Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calaspargase Pegol-Mnkl and Cobimetinib in Pancreatic Cancer
NCT05034627Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calaspargase pegol and cobimetinib in pancreatic adenocarcinoma (PDAC), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of dose-limiting toxicities. Started Aug 2022; status: completed.
02
Drugs
calaspargase pegolcobimetinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05034627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034627.